Filing Details
- Accession Number:
- 0000899243-20-028359
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-10-15 19:18:28
- Reporting Period:
- 2020-10-13
- Accepted Time:
- 2020-10-15 19:18:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1631650 | Aimmune Therapeutics Inc. | AIMT | Pharmaceutical Preparations (2834) | 452748244 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1803539 | S.a. Nestle Produits Des Societe | Avenue Nestle 55 Ch-1800, Vevey V8 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-10-13 | 43,435,583 | $34.50 | 43,435,583 | No | 4 | P | Indirect | See footnote |
| Common Stock | Acquisiton | 2020-10-13 | 10,681,704 | $34.50 | 23,408,817 | No | 4 | P | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 12,727,113 | Direct | |
| Series A Preferred Stock | 525,634 | Direct |
Footnotes
- All of the shares were cancelled on October 13, 2020 pursuant to the terms of that certain Agreement and Plan of Merger, dated as of August 29, 2020 (the "Merger Agreement"), by and among Societe des Produits Nestle S.A. ("SPN"), SPN MergerSub, Inc., a wholly owned subsidiary of SPN ("Merger Sub"), and Aimmune Therapeutics, Inc. ("Aimmune"). Following effectiveness of the merger provided for in the Merger Agreement, SPN owns 100 shares of the common stock of Aimmune, which became a wholly owned subsidiary of SPN as a result of such merger, which represents all of the outstanding shares of common stock of Aimmune.
- Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and SPN, pursuant to the Merger Agreement, for any and all outstanding shares of Aimmune common stock pursuant to that certain Offer to Purchase dated September 14, 2020.
- Shares acquired pursuant to the merger provided for in the Merger Agreement.
Billionaire Hedge Funds
